Free shipping on all orders over $ 500

ARQ 531

Cat. No. M9958

All AbMole products are for research use only, cannot be used for human consumption.

ARQ 531 Structure
Synonym:

ARQ-531;MK-1026; Nemtabrutinib

Size Price Availability Quantity
5mg USD 140  USD140 In stock
10mg USD 235  USD235 In stock
25mg USD 520  USD520 In stock
50mg USD 900  USD900 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ARQ 531 is a potent reversible inhibitor of BTK (IC50 = 0.85 nM), exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma. ARQ 531 targets multiple oncogenic signaling pathways in both ABC- and GCB-DLBCL cell lines. Unlike ibrutinib, ARQ 531 suppressed both the upstream activating signals (via inhibition of a select member of Src kinase family) and the downstream signaling pathways (via pAKT and pERK kinases). In GCB-DLBCL cell lines (SUDHL-4 and DOHH-2), ARQ 531 potently suppressed expression of anti-apoptotic c-Myc and BCL6 oncoproteins in a dose dependent fashion, and concomitantly induced apoptotic cleavage of PARP protein.

In the ibrutinib-resistant SUDHL-4 mouse xenograft model, ARQ 531 potently suppressed tumor growth (>80% inhibition) compared to the control group when dosed orally at 75 mg/kg. Additionally, preliminary data suggest that ARQ 531 crosses the blood, brain-barrier.

Chemical Information
Molecular Weight 478.93
Formula C25H23ClN4O4
CAS Number 2095393-15-8
Solubility (25°C) DMSO ≥ 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Sudharshan Eathiraj, et al. AACR. ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma

Related BTK Products
BIIB129

BIIB129 is a covalent, selective inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells.

UBX-382 

UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling.

GDC-0834 

GDC-0834 is a potent and selective BTK inhibitor.

DD-03-171 

DD-03-171 is a BTK, IKFZ1 and IKFZ3 degrader, the BTK IC50 a value of 5.1 nM.

N-piperidine Ibrutinib hydrochloride 

N-piperidine Ibrutinib hydrochloride is a reversible Ibrutinib derivative.

  Catalog
Abmole Inhibitor Catalog




Keywords: ARQ 531, ARQ-531;MK-1026; Nemtabrutinib supplier, BTK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.